86 related articles for article (PubMed ID: 18757264)
1. Correlation among [18F]fluorodeoxyglucose positron emission tomography/computed tomography, cancer antigen 27.29, and circulating tumor cell testing in metastatic breast cancer.
Saad A; Kanate A; Sehbai A; Marano G; Hobbs G; Abraham J
Clin Breast Cancer; 2008 Aug; 8(4):357-61. PubMed ID: 18757264
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
[TBL] [Abstract][Full Text] [Related]
3. F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the follow-up of breast cancer with elevated levels of tumor markers.
Haug AR; Schmidt GP; Klingenstein A; Heinemann V; Stieber P; Priebe M; la Fougère C; Becker C; Hahn K; Tiling R
J Comput Assist Tomogr; 2007; 31(4):629-34. PubMed ID: 17882045
[TBL] [Abstract][Full Text] [Related]
4. 18F-FDG-PET/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging: a multicentre study.
Grassetto G; Fornasiero A; Otello D; Bonciarelli G; Rossi E; Nashimben O; Minicozzi AM; Crepaldi G; Pasini F; Facci E; Mandoliti G; Marzola MC; Al-Nahhas A; Rubello D
Eur J Radiol; 2011 Dec; 80(3):828-33. PubMed ID: 20547020
[TBL] [Abstract][Full Text] [Related]
5. [Which is the best monitoring study (tumor marker, computed tomography or 18F-fluoro-2-deoxy-D-glucose positron emission tomography) to evaluate efficacy of chemotherapy on unresectable pancreatic cancer ?].
Kobayashi N; Fujita K; Fujisawa T; Takahashi H; Yoneda M; Abe Y; Inamori M; Kirikoshi H; Kubota K; Saito S; Nakajima A
Gan To Kagaku Ryoho; 2008 Jan; 35(1):65-70. PubMed ID: 18195530
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography of breast cancer in detecting axillary lymph node metastasis: comparison with ultrasonography and contrast-enhanced CT.
Monzawa S; Adachi S; Suzuki K; Hirokaga K; Takao S; Sakuma T; Hanioka K
Ann Nucl Med; 2009 Dec; 23(10):855-61. PubMed ID: 19876704
[TBL] [Abstract][Full Text] [Related]
7. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.
Billé A; Pelosi E; Skanjeti A; Arena V; Errico L; Borasio P; Mancini M; Ardissone F
Eur J Cardiothorac Surg; 2009 Sep; 36(3):440-5. PubMed ID: 19464906
[TBL] [Abstract][Full Text] [Related]
8. Detection of hematogenous bone metastasis in cervical cancer: 18F-fluorodeoxyglucose-positron emission tomography versus computed tomography and magnetic resonance imaging.
Liu FY; Yen TC; Chen MY; Lai CH; Chang TC; Chou HH; Hong JH; Chen YR; Ng KK
Cancer; 2009 Dec; 115(23):5470-80. PubMed ID: 19739235
[TBL] [Abstract][Full Text] [Related]
9. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques.
Koolen BB; Vrancken Peeters MJ; Aukema TS; Vogel WV; Oldenburg HS; van der Hage JA; Hoefnagel CA; Stokkel MP; Loo CE; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
Breast Cancer Res Treat; 2012 Jan; 131(1):117-26. PubMed ID: 21935602
[TBL] [Abstract][Full Text] [Related]
11. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site.
Pelosi E; Pennone M; Deandreis D; Douroukas A; Mancini M; Bisi G
Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):15-22. PubMed ID: 16557200
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
Messa C; Ceresoli GL; Rizzo G; Artioli D; Cattaneo M; Castellone P; Gregorc V; Picchio M; Landoni C; Fazio F
Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):259-66. PubMed ID: 16172572
[TBL] [Abstract][Full Text] [Related]
13. Comparison of physical examination and fluorodeoxyglucose positron emission tomography/computed tomography 4-6 months after radiotherapy to assess residual head-and-neck cancer.
Zundel MT; Michel MA; Schultz CJ; Maheshwari M; Wong SJ; Campbell BH; Massey BL; Blumin J; Wilson JF; Wang D
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e825-32. PubMed ID: 21300450
[TBL] [Abstract][Full Text] [Related]
14. F-18 FDG PET/CT in the management of thyroid cancer.
Iagaru A; Kalinyak JE; McDougall IR
Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020
[TBL] [Abstract][Full Text] [Related]
15. Identification of distant metastases with positron-emission tomography-computed tomography in patients with previously untreated head and neck cancer.
Gourin CG; Watts TL; Williams HT; Patel VS; Bilodeau PA; Coleman TA
Laryngoscope; 2008 Apr; 118(4):671-5. PubMed ID: 18197136
[TBL] [Abstract][Full Text] [Related]
16. Incidental PET/CT findings in the cancer patient: how should they be managed?
Beatty JS; Williams HT; Aldridge BA; Hughes MP; Vasudeva VS; Gucwa AL; David GS; Lind DS; Kruse EJ; McLoughlin JM
Surgery; 2009 Aug; 146(2):274-81. PubMed ID: 19628085
[TBL] [Abstract][Full Text] [Related]
17. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer.
De Giorgi U; Mego M; Rohren EM; Liu P; Handy BC; Reuben JM; Macapinlac HA; Hortobagyi GN; Cristofanilli M; Ueno NT
J Nucl Med; 2010 Aug; 51(8):1213-8. PubMed ID: 20660382
[TBL] [Abstract][Full Text] [Related]
19. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer.
Madhavan D; Zucknick M; Wallwiener M; Cuk K; Modugno C; Scharpff M; Schott S; Heil J; Turchinovich A; Yang R; Benner A; Riethdorf S; Trumpp A; Sohn C; Pantel K; Schneeweiss A; Burwinkel B
Clin Cancer Res; 2012 Nov; 18(21):5972-82. PubMed ID: 22952344
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer recurrence diagnosis suspected on tumor marker rising: value of whole-body 18FDG-PET/CT imaging and impact on patient management.
Champion L; Brain E; Giraudet AL; Le Stanc E; Wartski M; Edeline V; Madar O; Bellet D; Pecking A; Alberini JL
Cancer; 2011 Apr; 117(8):1621-9. PubMed ID: 21472709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
